Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to determine whether impaired glucose tolerance is improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Treatments: Hydrochlorothiazide; Losartan; Trandolapril; Verapamil

Criteria

Inclusion Criteria:

• Metabolic syndrome

• Fasting blood glucose between 100 mg/dL and 125 mg/dL

• Hypertension

• One additional criteria, Exclusion 1

Exclusion Criteria:

• Subject has a current diagnosis of Type 1 or Type 2 diabetes mellitus.

• Subject has a hypersensitivity to ACE inhibitor, ARB, CCB, clonidine, methyldopa, hydralazine, or thiazide diuretic medication.